Actuate Therapeutics (ACTU) said Tuesday that its phase 2 trial of elraglusib with gemcitabine/nab-paclitaxel, or GnP, in metastatic pancreatic cancer met primary endpoints of one-year survival rate.
The study demonstrated a one-year survival rate of 43.6% in the elraglusib-GnP arm compared to 22.5% in the GnP control arm. Median overall survival was 9.3 months for the elraglusib combination versus 7.2 months for GnP alone, Actuate said.
Actuate said it plans to share topline data and discuss next steps, including a phase 3 registration trial, with the US Food and Drug Administration in H1 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.